WO2016101412A1 - 一种无结晶水二丁酰环磷腺苷钙晶型及其制备方法和应用 - Google Patents

一种无结晶水二丁酰环磷腺苷钙晶型及其制备方法和应用 Download PDF

Info

Publication number
WO2016101412A1
WO2016101412A1 PCT/CN2015/073668 CN2015073668W WO2016101412A1 WO 2016101412 A1 WO2016101412 A1 WO 2016101412A1 CN 2015073668 W CN2015073668 W CN 2015073668W WO 2016101412 A1 WO2016101412 A1 WO 2016101412A1
Authority
WO
WIPO (PCT)
Prior art keywords
crystal form
cyclic adenosine
water
dibutyryl
crystal
Prior art date
Application number
PCT/CN2015/073668
Other languages
English (en)
French (fr)
Inventor
黄臻辉
杨柳青
霍建丽
朱鑫磊
丁金国
张志刚
Original Assignee
上海上药第一生化药业有限公司
上海紫源制药有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 上海上药第一生化药业有限公司, 上海紫源制药有限公司 filed Critical 上海上药第一生化药业有限公司
Priority to US15/525,049 priority Critical patent/US10420787B2/en
Priority to EP15871490.7A priority patent/EP3239162A4/en
Publication of WO2016101412A1 publication Critical patent/WO2016101412A1/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574—Esters of oxyacids of phosphorus
    • C07F9/65744—Esters of oxyacids of phosphorus condensed with carbocyclic or heterocyclic rings or ring systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
    • G01N21/35—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N23/00—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
    • G01N23/20—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials
    • G01N23/20075—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials by measuring interferences of X-rays, e.g. Borrmann effect
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N25/00—Investigating or analyzing materials by the use of thermal means
    • G01N25/20—Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity
    • G01N25/48—Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity on solution, sorption, or a chemical reaction not involving combustion or catalytic oxidation
    • G01N25/4846—Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity on solution, sorption, or a chemical reaction not involving combustion or catalytic oxidation for a motionless, e.g. solid sample
    • G01N25/4866—Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity on solution, sorption, or a chemical reaction not involving combustion or catalytic oxidation for a motionless, e.g. solid sample by using a differential method

Definitions

  • the invention relates to the field of medicines, in particular to a crystal form of water-free dibutyryl cyclic adenosine monophosphate and a preparation method and application thereof.
  • Calcium dibutyryl adenosine is a product obtained by forming a calcium salt of a cyclic adenosine monophosphate (cAMP) derivative.
  • Calcium adenosine diphosphate acts as a protein kinase activator that activates both protein kinase A and protein kinase C (cAMP only activates protein kinase A).
  • a protein kinase is an allosteric enzyme consisting of two catalytic subunits and two regulatory subunits that catalyze the phosphorylation of proteins (or enzymes).
  • calcium adenosine diphosphate can catalyze the most basic biochemical metabolism in the human body - oxidative phosphorylation and tricarboxylic acid cycle, which will activate most proteins and enzymes, activate various reactions of the human body, and produce a large amount of ATP, improving Cell and energy metabolism, thereby promoting its role in promoting nerve regeneration, transforming abnormal cells, dilating blood vessels, relaxing smooth muscle, and improving myocardial ischemia.
  • Calcium dibutyryl adenosine monophosphate is mainly used for the treatment of angina pectoris and acute myocardial infarction. It can also be used for the treatment of myocarditis, cardiogenic shock, subretinal hemorrhage and psoriasis after surgery, and also as an auxiliary anticancer drug. Clinical treatment, such as leukemia.
  • the dibutyryl cyclic adenosine monophosphate calcium drug substance or its injection preparation is prone to drug degradation during the effect period to produce related substances, thereby increasing adverse drug reactions, such as anaphylactic shock, heart failure, placental teratogenicity and the like. It is found that the root cause is the instability defect of calcium dibutyryl cyclic adenosine.
  • polymorphic variants Different crystal forms of a compound are referred to as “polymorphic variants” or “polymorphs.”
  • Polymorph Although the materials have the same chemical structure, their differences in packing arrangement and geometric arrangement lead to significant differences in drug stability and bioavailability, which directly affect the stability of the drug and its efficacy. Therefore, the relatively stable drug crystal form is of great value for improving the clinical efficacy of the drug during the efficacy period.
  • the technical problem to be solved by the present invention is to overcome the defects of unstable drug quality in the amorphous phase of dibutyryl cyclic adenosine monophosphate in the prior art, and to provide a crystal form of water-free dibutyryl cyclic adenosine monophosphate and preparation thereof.
  • the invention relates to a pharmaceutical composition without crystal water dibutyryl cyclic adenosine calcium crystal form and a preparation method thereof, and a crystal water-free dibutyryl cyclic adenosine monophosphate crystal form for preparing a medicament for treating cardiovascular and cerebrovascular diseases.
  • the crystal-free water dibutyryl cyclic adenosine calcium crystal form of the invention has high purity, good stability, simple preparation method, good reproducibility and convenient industrialization and application.
  • the relative intensities of the characteristic peaks at a diffraction angle of 2 ⁇ are as follows:
  • the powder X-ray diffraction pattern of the crystal water-free dibutyryl cyclic adenosine crystal form is shown in FIG.
  • the infrared spectrum of the crystal water-free dibutyryl cyclic adenosine crystal form has an infrared absorption characteristic peak at wave numbers of 2974, 1751, 1704, 1619, 1465, 1256, 1105, and 1022 cm -1 .
  • the infrared spectrum of the crystal water-free dibutyryl cyclic adenosine crystal form is shown in FIG. 2 .
  • the maximum absorption peak is obtained at 120 ° C to 170 ° C; preferably, at 149.4 ° C
  • the maximum absorption peak more preferably, the differential scanning calorimetry pattern of the crystal water-free dibutyryl cyclic adenosine crystal form is shown in FIG.
  • the invention also provides a preparation method of the crystal water-free dibutyryl cyclic adenosine calcium crystal form, which comprises the steps of: mixing anhydrous dibutyryl adenosine calcium solid with a solvent, heating and dissolving, decolorizing activated carbon, filtering Insoluble matter, an anti-solvent is added to the filtrate, and the mixture is cooled and stirred to obtain crystals.
  • the solvent is preferably one or more of methanol, ethanol, isopropanol, ethylene glycol, acetonitrile, tetrahydrofuran, dioxane, ethyl acetate, dichloromethane, acetone, and chloroform.
  • the anti-solvent is preferably one or more of n-hexane, n-pentane, diethyl ether, diisopropyl ether, methyl tert-butyl ether and toluene.
  • the ratio of the solvent to the volumetric mass of the anhydrous dibutyryl adenosine calcium solid is preferably 2 to 10 mL/g.
  • the temperature at which the heat is dissolved is preferably from 25 to 60 °C.
  • the quality of the activated carbon and the anhydrous dibutyryl adenosine calcium solid is preferably (0.01-0.1):1.
  • the anhydrous dibutyryl cyclic adenosine calcium solid is preferably anhydrous dibutyryl cyclic adenosine monophosphate.
  • the temperature of the cooling and stirring crystallization is preferably -25 to 25 °C.
  • the manner of adding the anti-solvent is preferably dropwise, and the rate of the dropwise addition is preferably 0.3 to 2.0 mL/min.
  • the time of the cooling and stirring crystallization is preferably 1 to 24 hours.
  • the present invention further provides a pharmaceutical composition
  • a pharmaceutical composition comprising the crystalline calcium dibutyryl adenosine monophosphate crystal form as described above and a pharmaceutically acceptable carrier.
  • the present invention still further provides a method for producing a pharmaceutical composition as described above, comprising the steps of: mixing a crystal form of water-free dibutyryl cyclic adenosine monophosphate as described above and a pharmaceutically acceptable carrier, Just fine.
  • the invention further provides the use of the above crystal-free water dibutyryl cyclic adenosine calcium crystal form for preparing a medicament for treating cardiovascular and cerebrovascular diseases in humans.
  • XRPD powder X-ray diffraction
  • IR infrared spectroscopy
  • DSC differential scanning calorimetry
  • HPLC means high performance liquid chromatography
  • MS mass spectrometry
  • antisolvent refers to a solvent that is miscible with the solvent and does not dissolve the solute.
  • the crystallized water-free dibutyryl cyclic adenosine calcium crystal form provided by the present invention is determined by XRPD pattern, IR spectrum and DSC pattern.
  • the reagents and starting materials used in the present invention are commercially available.
  • the crystal-free water dibutyryl adenosine calcium crystal form of the invention has high purity, good stability, simple preparation method, good reproducibility, and is convenient for industrialization and application.
  • Fig. 1 is a powder X-ray diffraction pattern of a crystal form of water-free dibutyryl cyclic adenosine monophosphate obtained by the present invention.
  • Fig. 2 is an infrared spectrum (IR) of the crystalline form of water-free dibutyryl cyclic adenosine monophosphate obtained by the present invention.
  • Fig. 3 is a differential scanning calorimetry chart (DSC) of the crystal form of water-free dibutyryl cyclic adenosine monophosphate obtained by the present invention.
  • Figure 4 is a powder X-ray diffraction pattern (XRPD) of an anhydrous dibutyryl adenosine calcium solid.
  • the crystal-free water dibutyryl cyclic adenosine calcium crystal form provided by the present invention is determined by XRPD pattern, IR spectrum and DSC pattern.
  • Powder X-ray diffraction was carried out using a D8 ADVANCE X-ray powder diffractometer from BRUKER-AXS, Germany. The test conditions were:
  • Cu target K ⁇ light source ( ), working voltage 40KV, working current 40mA, step size 0.02, scanning speed 0.3 seconds / step, scanning angle 1.5 ° ⁇ 60.0 °.
  • the nuclear magnetic resonance spectroscopy method was performed using Bruker's Avance III 400 MHz. Test method: 5 mg of dibutyryl cyclic adenosine monophosphate raw material or crystal form was placed in a nuclear magnetic tube and dissolved in hydrophobic water, and a nuclear magnetic resonance spectrum was obtained by scanning.
  • the mass spectrometry method was performed by American Waters ACQUITYTM UPLC&Q-TOF MS Premier.
  • the column was a Waters Acquity BEH C18 column (2.1 ⁇ 100 mm, 1.7 ⁇ m), the tandem mass spectrometer ion source was an electrospray ion source (ESI), positive ion scan mode detection, capillary voltage was 3.0 kV, and ion source temperature was 100 ° C.
  • the atomizing gas temperature was 350 ° C, the atomizing gas flow rate was 600.0 L ⁇ hr-1, and the collision voltage was 4.0 eV (MS) and 15.0 to 30.0 eV (MS/MS), respectively, and the scanning range was m/z 100 to 1000.
  • HPLC method was performed by American Waters 2695 high performance liquid chromatograph, autosampler, Waters 2489 UV/Vis detector, and Empower 2 data processing system. Chromatographic conditions:
  • the anhydrous dibutyryl adenosine calcium solid, DBC-Ca ⁇ 2.3H 2 O crystal (dibutyryl adenosine calcium hydrate 2.3 water) in the following examples was purchased from Shanghai First Biochemical Pharmaceutical Co., Ltd.
  • Example 7 Crystalline water-free dibutyryl cyclic adenosine calcium crystal form X-ray powder diffraction detection
  • Powder X-ray diffraction was performed using a German BRUKER-AXS D8 ADVANCE powder X-ray diffractometer under the following conditions: Cu target, K ⁇ I light source ( ), working voltage 40KV, working current 40mA, step size 0.02, scanning speed 0.3 seconds / step.
  • the scanning angle is 1.5° to 60.0°.
  • the powder X-ray diffraction patterns of the crystals of water-free dibutyryl cyclic adenosine monophosphate obtained in Examples 1 to 6 are shown in Fig. 1, in which the diffraction angle 2 ⁇ value, the interplanar spacing, and the characteristic peak of each characteristic peak are shown.
  • the relative strength parameters are shown in the following table:
  • the crystal of water without crystallized dibutyryl cyclic adenosine phosphate provided by the present invention is imaged by KBr compression and scanned from 400 to 4000 cm -1 , as shown in FIG. 2 , the characteristic peak position of the infrared spectrum is 2974, 1751. , 1704, 1619, 1465, 1256, 1105, 1022 cm -1 .
  • Example 9 Crystalline water-free dibutyryl cyclic adenosine calcium crystal form differential scanning calorimetry
  • the reference material is an Al pot (pan Al), the atmosphere is N 2 , the temperature reference is metal indium, the heating rate is 10 K/min, and the temperature rise range is 0-300 ° C.
  • the DSC spectrum is shown in Fig. 3. It has a maximum endothermic absorption peak at 120 °C - 170 °C, especially at 149.4 °C, and the melting enthalpy is about 26.97 J/g.
  • Example 10 Anhydrous dibutyryl adenosine calcium solid X-ray powder diffraction detection
  • test conditions were the same as those in Example 7, and the X-ray powder diffraction pattern was as shown in Fig. 4, and the results were shown to be substantially amorphous.
  • the nuclear magnetic resonance spectroscopy method was performed using Bruker's Avance III 400 MHz.
  • the test method was as follows: 5 mg of anhydrous dibutyryl adenosine calcium solid bulk drug was placed in a nuclear magnetic tube and dissolved in hydrophobic water, and a nuclear magnetic resonance spectrum was obtained by scanning.
  • the mass spectrometry method was performed by American Waters ACQUITYTM UPLC&Q-TOF MS Premier.
  • the column was a Waters Acquity BEH C18 column (2.1 ⁇ 100 mm, 1.7 ⁇ m), the tandem mass spectrometer ion source was an electrospray ion source (ESI), positive ion scan mode detection, capillary voltage was 3.0 kV, and ion source temperature was 100 ° C.
  • the atomizing gas temperature was 350 ° C, the atomizing gas flow rate was 600.0 L ⁇ hr-1, and the collision voltage was 4.0 eV (MS) and 15.0 to 30.0 eV (MS/MS), respectively, and the scanning range was m/z 100 to 1000.
  • the molecular ion peak m/z was found to be 469.4.
  • Example 13 Accelerated test and stability of long-term sample retention at room temperature

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

本发明公开了一种无结晶水二丁酰环磷腺苷钙晶型及其制备方法和应用。该无结晶水二丁酰环磷腺苷钙晶型在使用辐射源为Cu-Kα的粉末X-射线衍射图谱中，在衍射角2θ＝12.3°±0.2°、17.6°±0.2、21.4°±0.2°、24.7°±0.2、25.3°±0.2°和27.8°±0.2°处有特征峰。本发明的无结晶水二丁酰环磷腺苷钙晶型纯度高、稳定性好、制备方法简便，而且重现性好，便于工业化推广应用。

Description

一种无结晶水二丁酰环磷腺苷钙晶型及其制备方法和应用
本申请要求申请日为2014年12月24日的中国专利申请CN201410840112.8的优先权。本申请引用上述中国专利申请的全文。
技术领域
本发明涉及药物领域，具体涉及一种无结晶水二丁酰环磷腺苷钙晶型及其制备方法和应用。
背景技术
二丁酰环磷腺苷钙为环磷腺苷(cAMP)丁酰化衍生物成钙盐后制得的产品。二磷酸腺苷钙作为蛋白激酶激活剂，可同时激活蛋白激酶A和蛋白激酶C(cAMP仅激活蛋白激酶A)。蛋白激酶是一种别构酶，由两个催化亚基和两个调节亚基组成，催化亚基具有催化蛋白质(或酶)磷酸化作用。故二磷酸腺苷钙可催化人体内最基本的生物化学代谢——氧化磷酸化反应和三羧酸循环，使大多数蛋白质和酶类产生活性，激活人体各种反应，同时产生大量ATP，改善细胞和能量代谢，从而实现其促进神经再生、转化异常细胞、扩张血管、舒张平滑肌、改善心肌缺血等作用。
二丁酰环磷腺苷钙临床上主要用于心绞痛、急性心肌梗死的治疗，亦可用于治疗心肌炎、心源性休克、手术后网膜下出血和银屑病，也可作为辅助抗癌药物用于临床治疗，如白血病等。
但是，二丁酰环磷腺苷钙无定型物原料药或其注射制剂在效期内易发生药物降解而产生相关物质，从而增加药物不良反应，如过敏性休克致心衰死亡、胎盘致畸等。经研究发现，其根本原因在于二丁酰环磷腺苷钙的不稳定性缺陷。
一个化合物的不同晶型被称作“多晶型变体”或“多晶型物”。多晶型 物虽有相同的化学结构，但它们在堆积排列和几何排列方面的不同会导致药物稳定性、生物利用度等方面的显著差异，从而直接影响药物质量稳定及其疗效。因此，较为稳定的药物晶型对提高效期内药物临床疗效具有极为重要的价值。
发明内容
本发明所要解决的技术问题即在于克服现有技术中二丁酰环磷腺苷钙无定形物效期内药物质量不稳定的缺陷，提供一种无结晶水二丁酰环磷腺苷钙晶型及其制备方法，以及无结晶水二丁酰环磷腺苷钙晶型物的药物组合物及其制备方法，以及无结晶水二丁酰环磷腺苷钙晶型物在制备治疗心脑血管疾病药物中的应用。本发明的无结晶水二丁酰环磷腺苷钙晶型纯度高、稳定性好、制备方法简便，而且重现性好，便于工业化推广应用。
本发明是通过以下技术方案解决上述技术问题的：
本发明提供了一种无结晶水二丁酰环磷腺苷钙晶型，所述的无结晶水二丁酰环磷腺苷钙晶型在使用辐射源为Cu-Kα的粉末X-射线衍射图谱中，在衍射角2θ＝12.3°±0.2°、17.6°±0.2、21.4°±0.2°、24.7°±0.2、25.3°±0.2°和27.8°±0.2°处有特征峰。
其中较佳地，所述的粉末X-射线衍射图谱中，在衍射角2θ＝5.3°±0.2°、18.0°±0.2°、33.2°±0.2°、35.2°±0.2°、37.4°±0.2°、39.2°±0.2°、43.4°±0.2°和50.8°±0.2°还有次要峰。
其中较佳地，衍射角为2θ时的特征峰的相对强度如下表所示：
Figure PCTCN2015073668-appb-000001
Figure PCTCN2015073668-appb-000002
本发明中，所述的无结晶水二丁酰环磷腺苷钙晶型的粉末X-射线衍射图谱如图1所示。
本发明中，所述的无结晶水二丁酰环磷腺苷钙晶型的红外光谱图中，在波数为2974、1751、1704、1619、1465、1256、1105和1022cm-1处有红外吸收特征峰；较佳地，所述的无结晶水二丁酰环磷腺苷钙晶型的红外光谱图如图2所示。
本发明中，所述的无结晶水二丁酰环磷腺苷钙晶型的差示扫描量热法图谱(DSC)中，在120℃～170℃有最大吸收峰；较佳地，在149.4℃有最大吸收峰；更佳地，所述的无结晶水二丁酰环磷腺苷钙晶型的差示扫描量热法图谱如图3所示。
本发明还提供了所述的无结晶水二丁酰环磷腺苷钙晶型的制备方法，其包括下述步骤：将无水二丁酰环磷腺苷钙固体与溶剂混合，加热溶解，活性炭脱色，过滤不溶物，在滤液中加入反溶剂，降温搅拌析晶，即得。
其中，所述的溶剂较佳地为甲醇、乙醇、异丙醇、乙二醇、乙腈、四氢呋喃、二氧六环、乙酸乙酯、二氯甲烷、丙酮和氯仿中的一种或多种。
其中，所述的反溶剂较佳地为正己烷、正戊烷、乙醚、异丙醚、甲基叔丁基醚和甲苯中的一种或多种。
其中，所述的溶剂与所述的无水二丁酰环磷腺苷钙固体的体积质量较佳的比为2～10mL/g。
其中，所述的加热溶解的温度较佳的为25～60℃。
其中，所述的活性炭与所述的无水二丁酰环磷腺苷钙固体的质量比较佳的为(0.01-0.1)：1。
本发明中，所述的无水二丁酰环磷腺苷钙固体较佳地为无水二丁酰环磷腺苷钙无定形物。
其中，所述的降温搅拌析晶的温度较佳地为-25～25℃。
其中，所述的反溶剂的加入方式较佳地为滴加，所述的滴加的速率较佳地为0.3～2.0mL/min。
其中，所述的降温搅拌析晶的时间较佳地为1～24h。
本发明又提供了一种药物组合物，所述的药物组合物包含有如上所述的无结晶水二丁酰环磷腺苷钙晶型和药学上可接受的载体。
本发明还又提供了一种如上所述的药物组合物的制备方法，其包括下述步骤：将如上所述的无结晶水二丁酰环磷腺苷钙晶型和药学上可接受的载体混合，即可。
本发明再提供了上述无结晶水二丁酰环磷腺苷钙晶型在制备治疗人类心脑血管疾病药物中的应用。
本发明中：术语“XRPD”是指粉末X-射线衍射；
术语“IR”是指红外光谱法；
术语“DSC”是指差示扫描量热法；
术语“HPLC”是指高效液相色谱法；
术语“1HNMR”是指核磁共振氢谱；
术语“MS”是指质谱法；
术语“反溶剂”是指能与溶剂混溶而不能溶解溶质的溶剂。
本发明提供的无结晶水二丁酰环磷腺苷钙晶型物，通过XRPD图谱、IR图谱和DSC图谱来测定。
在符合本领域常识的基础上，上述各优选条件，可任意组合，即得本发 明各较佳实例。
本发明所用试剂和原料均市售可得。
本发明的积极进步效果在于：
(1)本发明的无结晶水二丁酰环磷腺苷钙晶型纯度高、稳定性好、制备方法简便，而且重现性好，便于工业化推广应用。
(2)本发明对无结晶水二丁酰环磷腺苷钙晶型的数据采集、分析实验研究，有助于开发对水、光、热稳定的药物晶型，这有利于解决本领域长期以来存在的该药物效期内(原料药或注射制剂)储存期间有关物质增加的技术难题，有利于二丁酰环磷腺苷钙产品质量、临床疗效的提升。
附图说明
图1为本发明制备得到的无结晶水二丁酰环磷腺苷钙晶型的粉末X-射线衍射图谱。
图2为本发明制备得到的无结晶水二丁酰环磷腺苷钙晶型的红外光谱图(IR)。
图3为本发明制备得到的无结晶水二丁酰环磷腺苷钙晶型的差示扫描量热法图(DSC)。
图4为无水二丁酰环磷腺苷钙固体的粉末X-射线衍射图(XRPD)。
具体实施方式
本发明提供的无结晶水二丁酰环磷腺苷钙晶型，通过XRPD图谱、IR图谱和DSC图谱来测定。
(1)粉末X-射线衍射法
粉末X-射线衍射使用德国BRUKER-AXS公司的D8 ADVANCE X-射线粉末衍射仪，测试条件为：
Cu靶，Kα光源(
Figure PCTCN2015073668-appb-000003
)，工作电压40KV，工作电流40mA，步 长0.02，扫描速度0.3秒/步，扫描角度1.5°～60.0°。
(2)核磁共振氢谱检测方法
核磁共振氢谱检测方法使用Bruker公司AvanceⅢ400MHz，测试方法：将5mg二丁酰环磷腺苷钙原料药或晶型物放入核磁管中用氘水溶解，扫描得到核磁共振氢谱。
(3)质谱检测方法
质谱检测方法采用美国Waters公司ACQUITYTM UPLC&Q-TOF MS Premier，测试方法：
色谱柱为Waters Acquity BEH C18色谱柱(2.1×100mm，1.7μm)，串联质谱离子源为电喷雾离子源(ESI)，正离子扫描模式检测，毛细管电压为3.0kV，离子源温度为100℃，雾化气温度为350℃，雾化气流量为600.0L·hr-1，碰撞电压分别为4.0eV(MS)和15.0～30.0eV(MS/MS)，扫描范围m/z100～1000。
(4)HPLC检测方法
HPLC检测方法采用美国Waters 2695高效液相色谱仪，自动进样器，Waters 2489型UV/Vis检测器，Empower 2数据处理系统。色谱条件：
色谱柱：Diamonsil C18色谱柱(4.6×250mm，5μm)；流动相A为50mM甲酸胺(甲酸调节pH至3.0)-乙腈(90︰10)，流动相B为乙腈；梯度洗脱条件：0～5min时B从0％到15％，5～10min时B从15％到22％，10～11min时B从22％到25％，11～12min时B从25％到30％，12～13min时B从30％到90％，13～16min时B为90％；流速：1ml·min-1；柱温：30℃；检测波长：273nm；进样量：20μL。此条件下二丁酰环磷酰苷钙主峰的保留时间为11.5min左右。以下实施例均按此法检测HPLC纯度。
下述实施例中的无水二丁酰环磷腺苷钙固体、DBC-Ca·2.3H2O晶体(二丁酰环磷腺苷钙合2.3水)购于上海第一生化药业有限公司。
实施例1无结晶水二丁酰环磷腺苷钙晶型物制备
称取无水二丁酰环磷腺苷钙固体10g，加入甲醇40ml，加热搅拌溶解，加入0.3g活性炭脱色，搅拌15min，滤除不溶物，得到滤液。在滤液中缓慢滴加入100mL乙醚，滴加2h，保持室温，搅拌析晶8h，析出白色固体，固体经过滤，干燥，得到无结晶水二丁酰环磷腺苷钙晶型物。HPLC纯度95.4％。收率为88％。
实施例2无结晶水二丁酰环磷腺苷钙晶型物制备
称取无水二丁酰环磷腺苷钙固体10g，加入甲醇40ml，加热搅拌溶解，加入0.5g活性炭脱色，搅拌15min，滤除不溶物，得到滤液。在滤液中缓慢滴加入120mL甲苯，滴加2h，保持5-10℃，搅拌析晶5h，析出白色固体，固体经过滤，干燥，得到无结晶水二丁酰环磷腺苷钙结晶。HPLC纯度95.2％。收率为90％
实施例3无结晶水二丁酰环磷腺苷钙晶型物制备
称取无水二丁酰环磷腺苷钙固体10g，加入甲醇40ml、丙酮10mL，加热搅拌溶解，加入0.3g活性炭脱色，搅拌30min，滤除不溶物，得到滤液。在滤液中缓慢滴加入130mL甲基叔丁基醚，滴加3h，保持0-5℃，搅拌析晶5h，析出白色固体，固体经过滤，干燥，得到无结晶水二丁酰环磷腺苷钙结晶。HPLC纯度96.2％。收率为89％。
实施例4无结晶水二丁酰环磷腺苷钙晶型物制备
称取无水二丁酰环磷腺苷钙固体10g，加入乙醇35ml，加热搅拌溶解，加入0.5g活性炭脱色，搅拌15min，滤除不溶物，得到滤液。滤液中缓慢滴加入130mL甲基叔丁基醚，滴加3h，保持0-5℃，搅拌析晶5h，析出白色固体，固体经过滤，干燥，得到无结晶水二丁酰环磷腺苷钙结晶。HPLC纯度95.8％。收率为93％。
实施例5无结晶水二丁酰环磷腺苷钙晶型物制备
称取无水二丁酰环磷腺苷钙固体10g，加入乙醇35ml加热搅拌溶解，加入0.5g活性炭脱色，搅拌30min，滤除不溶物，得到滤液。在滤液中缓慢滴加入120mL正己烷，滴加3h，保持0-5℃，搅拌析晶8h，析出白色固体，固体经过滤，干燥，得到无结晶水二丁酰环磷腺苷钙结晶。HPLC纯度95.2％。收率为90％。
实施例6无结晶水二丁酰环磷腺苷钙晶型物制备
称取无水二丁酰环磷腺苷钙固体10g，加入异丙醇60ml加热搅拌溶解，加入0.5g活性炭脱色，搅拌15min，滤除不溶物，得到滤液。在滤液中缓慢滴加入120mL正己烷，滴加2h，保持5-10℃，搅拌析晶8h，析出白色固体，固体经过滤，干燥，得到无结晶水二丁酰环磷腺苷钙结晶。HPLC纯度95.3％。收率为89％。
实施例7无结晶水二丁酰环磷腺苷钙晶型物X-射线粉末衍射检测
粉末X-射线衍射使用德国BRUKER-AXS公司D8 ADVANCE粉末X-射线衍射仪，测试条件为：Cu靶，KαI光源(
Figure PCTCN2015073668-appb-000004
)，工作电压40KV，工作电流40mA，步长0.02，扫描速度0.3秒/步。扫描角度1.5°～60.0°。实施例1～6制得的无结晶水二丁酰环磷腺苷钙晶型物的粉末X-射线衍射图谱如图1所示，其中，各特征峰的衍射角2θ值、晶面间距以及特征峰的相对强度的参数如下表所示：
Figure PCTCN2015073668-appb-000005
Figure PCTCN2015073668-appb-000006
实施例8无结晶水二丁酰环磷腺苷钙晶型物红外光谱检测
德国Bruker公司EQUINOX 55红外光谱仪，测试方法：
本发明提供的无结晶水二丁酰环磷腺苷钙结晶用KBr压片并从400至4000cm-1扫描测得的IR图谱，如图2所示，该红外谱图的特征峰位置位于2974、1751、1704、1619、1465、1256、1105、1022cm-1。
实施例9无结晶水二丁酰环磷腺苷钙晶型物差示扫描量热法检测
德国Netzsch公司DSC 204 F1差示扫描量热仪，工作条件为：
参比物为Al锅(pan Al)，氛围为N2，温度基准物为金属铟，升温速率为10K/min，升温范围0-300℃。
结果显示，该无结晶水二丁酰环磷腺苷钙晶型物中不含有结晶水。
DSC谱图见图3，其在120℃-170℃有最大吸热吸收峰峰值，尤其在149.4℃有最大吸收峰，熔融焓约为26.97J/g。
实施例10无水二丁酰环磷腺苷钙固体X-射线粉末衍射检测
测试条件同实施例7，其X-射线粉末衍射检测图谱如图4所示，结果显示基本为无定形物。
实施例11无水二丁酰环磷腺苷钙固体的核磁共振氢谱(1HNMR)
核磁共振氢谱检测方法使用Bruker公司Avance Ⅲ 400MHz，测试方法：为将5mg无水二丁酰环磷腺苷钙固体原料药放入核磁管中用氘水溶解，扫描得到核磁共振氢谱。其结果数据为1HNMR(400MHz,D2O):δ＝8.58(s,1H)；8.37(s,1H)；6.29(s,1H)；5.64-5.61(d,1H)；5.12-5.06(m,1H)；4.46-4.37(m,1H)；4.28-4.20(m,2H)；2.51-2.40(m,4H)；1.69-1.53(m,4H)；0.93-0.88(t,3H)；0.87-0.83(t,3H)。
实施例12无水二丁酰环磷腺苷钙固体的质谱图(MS)
质谱检测方法采用美国Waters公司ACQUITYTM UPLC&Q-TOF MS Premier，测试方法：
色谱柱为Waters Acquity BEH C18色谱柱(2.1×100mm，1.7μm)，串联质谱离子源为电喷雾离子源(ESI)，正离子扫描模式检测，毛细管电压为3.0kV，离子源温度为100℃，雾化气温度为350℃，雾化气流量为600.0L·hr-1，碰撞电压分别为4.0eV(MS)和15.0～30.0eV(MS/MS)，扫描范围m/z100～1000。其检测得到分子离子峰m/z为469.4。
实施例13加速试验及室温长期留样稳定性考察
1、加速试验：将按实施例1制得的无结晶水二丁酰环磷腺苷钙晶型物以及无水二丁酰环磷腺苷钙固体、DBC-Ca·2.3H2O晶体(二丁酰环磷腺苷钙合2.3水)共5个批次样品按原料药包装(用药用低密度聚乙烯袋包装)，置于30℃、相对湿度为75±5％的恒温恒湿培养箱中，放置6个月，在试验的第1、2、3、6个月分别取样检测有关物质(HPLC检测方法检测)、含量，并与0月的结果进行比较，结果见表1。
表1无结晶水二丁酰环磷腺苷钙晶型物和无水固体粉末的湿热加速试验结果
Figure PCTCN2015073668-appb-000007
Figure PCTCN2015073668-appb-000008
2、长期留样稳定性试验：将按实施例1制得的无结晶水二丁酰环磷腺苷钙晶型物以及无水二丁酰环磷腺苷钙固体、DBC-Ca·2.3H2O晶体(二丁酰环磷腺苷钙合2.3水)共5个批次样品按原料药包装(用药用低密度聚乙烯袋包装)，置于16℃、相对湿度为60±5％的恒温恒湿培养箱中，放置12个月，在试验的第3、6、9、12个月分别取样检测有关物质(HPLC检测方法检测)、含量，并与0月的结果进行比较，结果见表2。
表2.无结晶水二丁酰环磷腺苷钙晶型物和无水固体粉末的长期稳定性试验结果
Figure PCTCN2015073668-appb-000009
Figure PCTCN2015073668-appb-000010
虽然以上描述了本发明的具体实施方式，但是本领域的技术人员应当理解，这些仅是举例说明，在不背离本发明的原理和实质的前提下，可以对这些实施方式做出多种变更或修改。因此，本发明的保护范围由所附权利要求书限定。

Claims (13)

  1. 一种无结晶水二丁酰环磷腺苷钙晶型，其特征在于，所述的无结晶水二丁酰环磷腺苷钙晶型在使用辐射源为Cu-Kα的粉末X-射线衍射图谱中，在衍射角2θ＝12.3°±0.2°、17.6°±0.2、21.4°±0.2°、24.7°±0.2、25.3°±0.2°和27.8°±0.2°处有特征峰。
  2. 如权利要求1所述的无结晶水二丁酰环磷腺苷钙晶型，其特征在于，所述的粉末X-射线衍射图谱中，在衍射角2θ＝5.3°±0.2°、18.0°±0.2°、33.2°±0.2°、35.2°±0.2°、37.4°±0.2°、39.2°±0.2°、43.4°±0.2°和50.8°±0.2°还有次要峰。
  3. 如权利要求1或2所述的无结晶水二丁酰环磷腺苷钙晶型，其特征在于，所述的粉末X-射线衍射图谱如图1所示。
  4. 如权利要求1～3中至少一项所述的无结晶水二丁酰环磷腺苷钙晶型，其特征在于，所述的无结晶水二丁酰环磷腺苷钙晶型的红外光谱图中，在波数为2974、1751、1704、1619、1465、1256、1105和1022cm-1处有红外吸收特征峰。
  5. 如权利要求1～4中至少一项所述的无结晶水二丁酰环磷腺苷钙晶型，其特征在于，所述的无结晶水二丁酰环磷腺苷钙晶型的红外光谱图如图2所示。
  6. 如权利要求1～5中至少一项所述的无结晶水二丁酰环磷腺苷钙晶型，其特征在于，所述的无结晶水二丁酰环磷腺苷钙晶型的差示扫描量热法图谱中，在120℃～170℃有最大吸收峰。
  7. 如权利要求6所述的无结晶水二丁酰环磷腺苷钙晶型，其特征在于，所述的无结晶水二丁酰环磷腺苷钙晶型的差示扫描量热法图谱中，在149.4℃有最大吸收峰。
  8. 如权利要求1～7中至少一项所述的无结晶水二丁酰环磷腺苷钙晶型， 其特征在于，所述的无结晶水二丁酰环磷腺苷钙晶型的差示扫描量热法图谱如图3所示。
  9. 如权利要求1～8中至少一项所述的无结晶水二丁酰环磷腺苷钙晶型的制备方法，其包括下述步骤：将无水二丁酰环磷腺苷钙固体与溶剂混合，加热溶解，活性炭脱色，过滤不溶物，在滤液中加入反溶剂，降温搅拌析晶，即得。
  10. 如权利要求9所述的制备方法，其特征在于，所述的溶剂为甲醇、乙醇、异丙醇、乙二醇、乙腈、四氢呋喃、二氧六环、乙酸乙酯、二氯甲烷、丙酮和氯仿中的一种或多种；
    和/或，所述的反溶剂为正己烷、正戊烷、乙醚、异丙醚、甲基叔丁基醚和甲苯中的一种或多种。
  11. 如权利要求9或10所述的制备方法，其特征在于，所述的溶剂与所述的无水二丁酰环磷腺苷钙固体的体积质量比为2～10mL/g；
    和/或，所述的加热溶解的温度为25～60℃；
    和/或，所述的活性炭与所述的无水二丁酰环磷腺苷钙固体的质量比为(0.01-0.1)：1；
    和/或，所述的无水二丁酰环磷腺苷钙固体为无水二丁酰环磷腺苷钙无定形物；
    和/或，所述的降温搅拌析晶的温度为-25～25℃；
    和/或，所述的反溶剂的加入方式为滴加；
    和/或，所述的降温搅拌析晶的时间为1～24h。
  12. 如权利要求11所述的制备方法，其特征在于，所述的滴加的速率为0.3～2.0 mL/min。
  13. 如权利要求1～8中至少一项所述的无结晶水二丁酰环磷腺苷钙晶型在制备治疗人类心脑血管疾病药物中的应用。
PCT/CN2015/073668 2014-12-24 2015-03-05 一种无结晶水二丁酰环磷腺苷钙晶型及其制备方法和应用 WO2016101412A1 (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US15/525,049 US10420787B2 (en) 2014-12-24 2015-03-05 Crystal-water-free calcium dibutyryladenosine cyclophosphate crystal form and preparation method and application thereof
EP15871490.7A EP3239162A4 (en) 2014-12-24 2015-03-05 Crystallization water-free calcium dibutyryladenosine cyclophosphate crystal form, and preparation method and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201410840112.8 2014-12-24
CN201410840112.8A CN104478979A (zh) 2014-12-24 2014-12-24 一种无结晶水二丁酰环磷腺苷钙晶型及其制备方法和应用

Publications (1)

Publication Number Publication Date
WO2016101412A1 true WO2016101412A1 (zh) 2016-06-30

Family

ID=52753600

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2015/073668 WO2016101412A1 (zh) 2014-12-24 2015-03-05 一种无结晶水二丁酰环磷腺苷钙晶型及其制备方法和应用

Country Status (4)

Country Link
US (1) US10420787B2 (zh)
EP (1) EP3239162A4 (zh)
CN (1) CN104478979A (zh)
WO (1) WO2016101412A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105343119B (zh) * 2015-11-19 2018-08-07 广东赛法洛医药科研有限公司 环磷酸腺苷或其衍生物在手术后网膜下出血中的应用
CN108997430B (zh) * 2018-07-16 2020-05-22 南京工业大学 一种二丁酰环磷腺苷钙盐的晶体
CN113527395B (zh) * 2021-09-17 2022-01-07 中国远大集团有限责任公司 一种腺苷的晶型及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1931180A (zh) * 2006-05-25 2007-03-21 武汉安士医药科技有限公司 具有不同性状的药物及其制备和用途
CN101172112A (zh) * 2007-05-25 2008-05-07 武汉安士医药科技有限公司 具有独特性质的化合物、含有该化合物的组合物及其制备方法和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6024118B2 (ja) * 1975-03-31 1985-06-11 第一製薬株式会社 アデノシン燐酸誘導体の製法
CN1554358A (zh) * 2003-12-23 2004-12-15 上海第一生化药业有限公司 二丁酰环磷腺苷钙制剂及制备方法
CN100457770C (zh) * 2006-12-06 2009-02-04 杭州美亚药业有限公司 二丁酰环磷腺苷钙的精制方法
CN103242403B (zh) * 2012-06-21 2016-01-20 北京赛盟医药科技发展有限公司 高纯度二丁酰环磷腺苷钙及其制备方法
CN104262436A (zh) * 2014-09-19 2015-01-07 北京赛盟医药科技发展有限公司 无定型二丁酰环磷腺苷钙无菌粉末

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1931180A (zh) * 2006-05-25 2007-03-21 武汉安士医药科技有限公司 具有不同性状的药物及其制备和用途
CN101172112A (zh) * 2007-05-25 2008-05-07 武汉安士医药科技有限公司 具有独特性质的化合物、含有该化合物的组合物及其制备方法和用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of EP3239162A4 *
ZHOU, QIAN ET AL.: "Improvement of the Synthesis Process of Calcium Dibutyryladenosine Cyclophosphate", PROCEEDINGS OF 2007 NATIONAL ACADEMIC ANNUAL CONFERENCE ON BIOCHEMICAL AND BIOLOGICAL TECHNOLOGY PHARMACEUTICAL, 31 December 2007 (2007-12-31), pages 472 - 474, XP009503942 *

Also Published As

Publication number Publication date
CN104478979A (zh) 2015-04-01
US20180050057A1 (en) 2018-02-22
US10420787B2 (en) 2019-09-24
EP3239162A4 (en) 2018-06-06
EP3239162A1 (en) 2017-11-01

Similar Documents

Publication Publication Date Title
EP3122753A2 (en) Ibrutinib solid forms and production process therefor
CN110402244A (zh) Lsd1抑制剂的盐
RU2704795C2 (ru) Кристаллическая форма бисульфата ингибитора jak и способ ее получения
KR20170137916A (ko) 우라실 화합물의 신규 결정
CN111777595A (zh) 一种环己烷甲酰胺类化合物的新晶型及其制备方法
KR102522895B1 (ko) Jak 키나아제 억제제 바이설페이트의 결정형 및 이의 제조방법
WO2016101412A1 (zh) 一种无结晶水二丁酰环磷腺苷钙晶型及其制备方法和应用
EP2855499A1 (en) Solid state forms of fidaxomycin and processes for preparation thereof
CN104829673B (zh) 一种索氟布韦晶型6的制备方法
CN108503560B (zh) 柳胺酚晶型ii、其制备方法及其应用
WO2020244348A1 (zh) 呋喃并咪唑并吡啶类化合物的合成方法、呋喃并咪唑并吡啶类化合物的晶型及其盐的晶型
WO2023193563A1 (zh) 一种噻吩并吡啶化合物的晶型a、制备方法及其药物组合物
KR20230008047A (ko) 니트록솔린 전구약물의 결정 형태, 이를 함유하는 약학 조성물, 및 이의 제조 방법 및 이의 용도
CN108727417B (zh) 多环化合物钠盐及其多晶型、制备方法及应用
CN113045554A (zh) 一种非索替尼晶型及其制备方法
CN104490798B (zh) 无结晶水二丁酰环磷腺苷钙晶型冻干粉针及其制备方法
CN107849051B (zh) 取代的氨基吡喃衍生物的晶型
CN112225730A (zh) 一种稠环化合物的晶型、其组合物、制备方法及其应用
JP2017530107A (ja) ナトリウム・グルコース共輸送体２阻害薬のｌ−プロリン化合物、およびｌ−プロリン化合物の一水和物および結晶
WO2002038545A2 (en) Crystalline ethanolate solvate form of zafirlukast, process for manufacture and pharmaceutical compositions thereof
WO2023131017A1 (zh) 一种稠环衍生物的晶型、其制备方法及其应用
CN114181211B (zh) 一种酮咯酸与苯甲酰胺共晶体及其制备方法
CN110730785B (zh) 一种脂肪酸胆汁酸偶合物的晶型及其制备方法和用途
WO2019105217A1 (zh) Galunisertib的晶型及其制备方法和用途
WO2018209667A1 (zh) 多环杂环化合物的晶型、其制备方法、应用及组合物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15871490

Country of ref document: EP

Kind code of ref document: A1

REEP Request for entry into the european phase

Ref document number: 2015871490

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 15525049

Country of ref document: US